RALEIGH, N.C., August 1 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR) today announced its filing of a 510(k) premarket notification
with the FDA seeking marketing clearance of its LIQUIDERM(TM) liquid adhesive
bandage ("LIQUIDERM") for use in the treatment of minor cuts, abrasions,
burns, minor irritations, and to help protect them from infection. The filing
is based in part on the findings of a 162 patient multi-center clinical study
conducted at the University of Miami, the Orlando Regional Healthcare System
and the Palm Beach Research Center.
In the multi-center study, LIQUIDERM(TM) liquid adhesive bandage was found
to: (1) stay on wounds better and longer than traditional adhesive bandages,
(2) seal wounds from dirt and germs, (3) minimize pain better than adhesive
bandages, (4) stop bleeding of minor cuts and abrasions and (5) require only
one application per treatment.
LIQUIDERM(TM) liquid adhesive bandage utilizes the same proprietary
technology as the Company's professional product DERMABOND(R) Topical Skin
Adhesive ("DERMABOND"). DERMABOND is used in hospitals as an alternative to
sutures and staples in closing incisions and lacerations. LIQUIDERM is simply
painted on the wound, sealing it from dirt and germs, creating a healing
environment, which allows natural healing to take place quickly. As the wound
heals, the adhesive sloughs off naturally.
"For over 75 years, the adhesive bandage category, a $1 billion worldwide
category, has seen limited major innovations with no new alternatives," said
Robert V. Toni, President and CEO. "LIQUIDERM(TM) liquid adhesive bandage
represents a transformational innovation with superior product benefits versus
traditional adhesive bandages. LIQUIDERM is more than just a covering for
wounds."
Mr. Toni continued, "LIQUIDERM(TM) liquid adhesive bandage is unlike
existing adhesive bandages, because it conforms to any wound size, stays on
bending and moving parts of the body and will not fall off when wet."
CLOSURE is currently in discussions with several top tier OTC marketing
companies with respect to the worldwide marketing rights to LIQUIDERM(TM)
liquid adhesive bandage, which is its second over-the-counter product.
CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina,
develops, manufactures and commercializes medical tissue adhesive products
based on its proprietary cyanoacrylate technology. CLOSURE's nonabsorbable
tissue adhesive products may be used to replace sutures and staples for
certain topical wound closure applications, while its internal tissue adhesive
products can potentially be used for internal wound closure and management.
Currently marketed nonabsorbable tissue adhesive products include
DERMABOND(R)* Topical Skin Adhesive, which is used to replace sutures and
staples for closure of certain lacerations and incisions, OCTYLDENT(R)*
adhesive, which is used as an adjunct in the treatment of adult periodontal
disease; and the NEXABAND(R)* line of topical adhesives, which are used in
veterinary wound closure and management.
* DERMABOND(R) adhesive is a trademark of Ethicon, Inc.; SOOTHE-N-SEAL(TM)
canker sore relief and LIQUIDERM(TM) adhesive are trademarks of CLOSURE
Medical Corporation. OCTYLDENT(R) adhesive and NEXABAND(R) adhesives are
federally registered trademarks of CLOSURE Medical Corporation.
To receive CLOSURE's latest news release and other corporate documents via
fax, at no cost, call 1-800-PRO-INFO, use the Company's symbol CLSR. Or visit
the Financial Relations Board's website at http://www.frbinc.com .
This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements. These factors
include, but are not limited to the early stage of commercialization of the
Company products; the progress of its research and development programs for
future products; the need for regulatory approval and effects of governmental
regulation; technological uncertainties; dependence on marketing partners, and
dependence on patents and trade secrets, as well as those detailed in the
Company's Annual Report on Form 10-K for the year ended December 31, 1999
filed with the Securities and Exchange Commission.
SOURCE Closure Medical Corp.
 back to top
Related links:
http://www.frbinc.com
CONTACT:
Robert V. Toni, President and CEO, or Benny
Ward, CFO of CLOSURE Medical Corp., 919-876-7800; General, Stuart
Levine, Analysts, Cecelia Heer, or Media, Deanne Eagle of The
Financial Relations Board, 212-661-8030
|
